Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL. In March 2004, the FDA approved Sensipar (cinacalcet HCI), and the Company signed a definitive agreement to acquire Tularik Inc.
Key Financial Metrics
| Metric (in millions) | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenues | $2,343.0 | $1,761.2 |
| Product Sales | $2,207.8 | $1,635.9 |
| Operating Income | $928.1 | $662.2 |
| Net Income | $690.2 | $493.3 |
| Diluted EPS | $0.52 | $0.37 |
| Cash from Operations | $398.6 | $780.8 |
| Cash & Equivalents (End of Period) | $761.5 | $2,340.2 |
| Convertible Notes (Current Liability) | $2,887.6 | $0 |
Note: Convertible Notes were reclassified as current liabilities in Q1 2004 due to put option dates approaching.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 33% ($581.8 million) year-over-year. Product sales grew 35% ($571.9 million), driven primarily by demand for Aranesp, Neulasta, and ENBREL.
- Profitability: Net income increased 40% ($196.9 million). Operating income rose 40% ($265.9 million).
- Expense Increases:
- R&D Expenses: Increased 26% ($90.0 million) due to higher staff costs, outside R&D costs, and clinical manufacturing.
- SG&A Expenses: Increased 36% ($136.0 million) driven by staff costs and marketing expenses, including Wyeth profit share for ENBREL.
- Cash Flow: Net cash provided by operating activities decreased 49% ($382.2 million) primarily due to the timing of accrued liability payments, despite higher earnings.
- Stock Repurchases: The Company repurchased 10.1 million shares for $649.7 million in Q1 2004, compared to 8.2 million shares for $450.6 million in Q1 2003.
Guidance, Outlook, and Risks
- Outlook: Near-term growth is expected to be driven by Aranesp, Neulasta, and ENBREL. EPOGEN growth is expected to approximate 4% patient population growth for the full year 2004.
- Capital Expenditures: Estimated spending for 2004 is between $1.3 billion and $1.5 billion, focused on the new ENBREL manufacturing plant in Rhode Island and Puerto Rico expansion.
- Acquisition: The proposed merger with Tularik Inc. (estimated price ~$1.5 billion) is expected to close in the second half of 2004, subject to shareholder and regulatory approval.
- Key Risks:
- Reimbursement: Potential adverse impact from the Medicare Prescription Drug Improvement and Modernization Act of 2003 and private insurer reimbursement reductions.
- Supply Constraints: ENBREL supply is dependent on third-party manufacturers (BI Pharma) and the Company's Rhode Island facility; shortages could materially affect sales.
- Patent Expirations: European patents for erythropoietin and G-CSF expire in late 2004 and mid-2006, respectively, potentially increasing competition.
- Legal Proceedings: Ongoing litigation regarding Average Wholesale Price (AWP) reporting and a class action lawsuit challenging the Tularik acquisition terms.
Investor Verification Checklist
- Verify the impact of the Medicare Prescription Drug Improvement and Modernization Act of 2003 on reimbursement rates for key products.
- Monitor the status of ENBREL manufacturing capacity, specifically the Rhode Island expansion and third-party agreements with BI Pharma and Genentech.
- Track the progress of the Tularik Inc. acquisition, including shareholder approval and regulatory clearance.
- Review the timeline for European patent expirations (Erythropoietin in Dec 2004, G-CSF in Aug 2006) and potential competitive entry.
- Assess the status of Average Wholesale Price (AWP) litigation and potential financial exposure.